Sonic Incytes Takes the Stage at LSI Emerging Medtech Summit
May 10, 2021
Sonic Incytes Medical Corp., the developers of VelacurTM, will take the stage at the LSI 2021 Emerging Medtech Summit to present its breakthrough solution for addressing fatty liver disease, an urgent, global health crisis exacerbated by the COVID-19 pandemic.
Held May 11-13 in California, this premier event connects start-ups that have developed the most innovative medical solutions with institutional investors and strategics.
On May 12, Sonic Incytes CEO George Aliphtiras is presenting VelacurTM, the first handheld 3D liver health assessment solution to tackle the fatty liver disease (NASH) crisis – a $2 billion plus market opportunity.
Sonic Incytes promises to be an asset to any portfolio having achieved strong results to date:
- FDA clearance of VelacurTM in late 2020, fast tracked
- Customer pilots with top US KOLs, providers and pharma
- Revenue generating.
For more information, visit https://www.lifesciencemarketresearch.com/medtech-summit/agenda.